Glaxo opens its books on malaria vax research

GlaxoSmithKline is opening up its in-house R&D work involving more than two million molecules in hopes of spurring some fresh thinking on malaria vaccines. CEO Andrew Witty, who's been intent on burnishing the company's reputation, says that Glaxo researchers have identified 13,500 compounds that show promise against malaria. And the Big Pharma exec says Glaxo will also donate all of its revenue from an experimental vaccine to help fund the fight against tropical diseases.

GSK assigned five scientists to screen its enormous small molecule library for new compounds that could fight malaria. It's also pursuing large trials of a new vaccine that GSK plans to file for approval in 2012.

"This is the furthest anybody's gone; nobody has put in the public domain the product of a two million screen" of small molecules, Witty said. "These are essentially the building blocks from which all of our drugs eventually come."

- here's the story from Bloomberg

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.